Antabio is a private European biopharmaceutical company developing novel and highly differentiated antibacterial treatments for WHO critical priority pathogens with a particular focus on life-threatening respiratory infections.
The company’s portfolio includes ANT3310 which addresses drug-resistant hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and the PEi program which is focused on chronic lung infections caused by Pseudomonas aeruginosa in CF patients. A third program, ANT2681, targets NDM-producing carbapenem-resistant Enterobacterales (CRE).
Antabio has built an international team with highly successful track records, including former executives/Manager from Novexel, Merck, GSK and Astra Zeneca.
The company has raised over €23m in non-dilutive financing to date from Wellcome Trust (2 SDD awards, 2013 and 2015) and CARB-X (2017). The company also completed a €12,5m series A round in 2017 with second closing in 2018.
